期刊
BIOMATERIALS SCIENCE
卷 10, 期 1, 页码 281-293出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d1bm01333e
关键词
-
资金
- National Health and Medical Research Council (NHMRC) [APP1132975, APP1158748]
This study identified a cyclic decapeptide that significantly enhances the adjuvant activity of several lipid-antigen mixtures, and three synthetic vaccine components were synthesized, including the cyclic carrier decapeptide. It was found that the presence of the cyclic peptide is necessary for inducing a strong, balanced Th1/Th2 immune response, compared to other mixtures without the cyclic peptide.
Untreated or reoccurring group A Streptococcus (GAS) infection can lead to a number of post-infection complications, including rheumatic heart disease. There is no licenced vaccine for the treatment or prevention of GAS infection. We identified that a cyclic decapeptide plays a significant positive influence on the adjuvant activity of several lipid-antigen mixtures. Here, three synthetic vaccine components were synthesised: (1) J8-PADRE represents the GAS B cell antigen (J8) conjugated to the universal T helper epitope (PADRE); (2) a synthetic toll like receptor 2 (TLR2) ligand based on a C16 alkyl chain lipid moiety; and (3) a cyclic carrier deca-peptide. Previously, through structure-immune activity investigations, it was observed that a physical mixture of these three components had significantly higher IgG immune responses when compared to a fully conjugated vaccine construct. Expanding the scope of this structure-activity investigation, we show that the presence of the cyclic peptide is required for the induction of a strong, balanced Th1/Th2 immune response when compared with lipid and antigen only, and cyclic lipopeptide plus B/T cell antigen physical mixtures.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据